Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Oncology·MeSH: Neoplasms
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Multikine | CEL SCI CORP (CVM) |
Phase 2(1)
| Drug | Company |
|---|---|
| cylembio | IO Biotech, Inc. (IOBT) |
Compare drugs
Frequently asked questions
How many drugs are in development for Squamous Cell Carcinoma of the Head and Neck (SCCHN)?
BioSniper tracks 2 drugs in development for Squamous Cell Carcinoma of the Head and Neck (SCCHN) across 2 companies.
How many clinical trials target Squamous Cell Carcinoma of the Head and Neck (SCCHN)?
There are 1 clinical trial targeting Squamous Cell Carcinoma of the Head and Neck (SCCHN) tracked by BioSniper.
What is the prevalence of Squamous Cell Carcinoma of the Head and Neck (SCCHN)?
The estimated prevalence of Squamous Cell Carcinoma of the Head and Neck (SCCHN) is approximately 14.0 per 100,000 population.
Deep-dive into Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis